stockrowAditxt, Inc.
ADTX Healthcare Biotechnology
Aditxt, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3,200.00, down 97.6% from fiscal 2024.
- Revenue
- +1,120.0%
- EPS
- +99.6%
- Free cash flow
- +60.8%
Quarter to March 2026, against a year earlier
Follow ADTX
Alert me
Aditxt, Inc. (ADTX) EV/Sales
As of 6 November 2026, Aditxt, Inc. (ADTX) trades at a EV/Sales of 73.3×. Over the past ten years it has ranged from −571× (March 2026) to 2,186,191,451× (August 2023); the current reading is higher than 64% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −304× | — |
| FY2024 | 3.6× | 90.77% |
| FY2023 | 1.9× | (100.00%) |
| FY2022 | 19,164,605× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 111× | — |
| Dec 2025 | −304× | — |
| Sep 2025 | 818× | 168.70% |
| Jun 2025 | 304× | 320.03% |
| 14 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CELZ Creative Medical Technology Holdings, Inc. compare | −378× |
| AZTR Azitra, Inc. compare | −9.1× |
| XBIO Xenetic Biosciences, Inc. compare | −0.3× |
| NCNA NuCana PLC Sponsored ADR compare | n/m |
| PMCB Nuvilex Inc. compare | n/m |
| NIKI Niki BioSolutions, Inc. compare | 1.3× |
| SKYE Skye Bioscience, Inc. compare | 3.6× |
| OSRH OSR Health, Inc. compare | 4.9× |
| ADTX Aditxt, Inc. | 73.3× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)